<DOC>
	<DOCNO>NCT01573923</DOCNO>
	<brief_summary>Liver cirrhosis subsequent liver failure lead cause morbidity mortality worldwide . Alcohol abuse viral hepatitis common cause cirrhosis . Novel therapy necessary prevent block process disease . In current prospective cohort , investigator plan organize four hospital determine safety efficacy intravenous administration umbilical mesenchymal stem cell treatment patient liver cirrhosis next three year .</brief_summary>
	<brief_title>Safety Efficacy Study Umbilical Mesenchymal Stem Cells Liver Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>write informed consent age 3060 year clinical diagnosis compensate decompensated liver childPugh B/C ( 712 point ) expect lifetime three year pregnant woman patient severe vascular disease patient organ failure patient tumor patient HIV patient transplant patient treated immunosuppressor patient followup consider impossible patient disease condition investigator treat physician feel would interfere trial safety subject</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Umbilical Mesenchymal Stem Cells ; Liver cirrhosis</keyword>
</DOC>